PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
6.22%
Cash & equivalents yoy growth below half of AGEN's 168.69%. Michael Burry would question if the firm faces a liquidity squeeze. Check for rising debts or negative cash flow.
-100.00%
Both AGEN and the company show zero Short-Term Investments Growth.
6.22%
Below half of AGEN's 168.69%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other current assets growth < half of AGEN's 172.27%. David Dodd sees a leaner approach to short-term items.
13.80%
Below half of AGEN's 167.12%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
2.11%
Below half AGEN's -25.75%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.11%
Below half of AGEN's 249.82%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
13.78%
Below half of AGEN's 210.91%. Michael Burry sees a potential red flag for stagnation or capital shortage.
62.36%
50-75% of AGEN's 101.43%. Bruce Berkowitz notes the company is paying suppliers faster or not stretching terms as competitor does.
-40.14%
Less than half of AGEN's 16.03%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
133.46%
≥ 1.5x AGEN's 82.56%. David Dodd sees stronger subscription/prepayment demand.
184.58%
1.25-1.5x AGEN's 126.34%. Martin Whitman sees a potentially higher near-term liability load.
173.41%
Above 1.5x AGEN's 39.60%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
173.41%
Above 1.5x AGEN's 14.51%. Michael Burry sees a potential leverage warning sign.
4.06%
Less than half of AGEN's 71.00%. David Dodd sees fewer share issuances vs. competitor.
-25.11%
≥ 1.5x AGEN's -0.01%. David Dodd sees higher yoy retained profits than competitor.
-90.06%
Less than half of AGEN's 100.78%. David Dodd sees fewer intangible or market-driven swings than competitor.
-100.00%
Similar yoy changes to AGEN's -100.00%. Walter Schloss finds parallel equity item fluctuations.
-763.59%
Below half AGEN's 1512.30%. Michael Burry sees potential underperformance in building shareholder capital.
13.78%
Below half AGEN's 210.91%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-100.00%
Both AGEN and the company show zero Total Investments Growth.
-40.14%
Less than half of AGEN's 5.57%. David Dodd sees less overall debt expansion vs. competitor.
-7.59%
Less than half of AGEN's -246.92%. David Dodd sees better deleveraging or stronger cash buildup than competitor.